Lykos’ MD­MA-as­sist­ed ther­a­py stum­bles at ad­comm amid ques­tions about study, safe­ty and abuse

An FDA ad­vi­so­ry com­mit­tee vot­ed against back­ing Lykos Ther­a­peu­tics’ MD­MA-based ther­a­py for post-trau­mat­ic stress dis­or­der, a blow to the biotech com­pa­ny’s ef­forts to bring the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.